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Objective: Vascular endothelial growth factor, a critical factor in angiogenesis, mediates stem cell paracrine pro-
tective effects on ischemic myocardium. Studies on the role of sex in stem cell function have demonstrated that
female mesenchymal stem cells produce greater vascular endothelial growth factor and provide better cardiac pro-
tection compared with male mesenchymal stem cells. The purpose of this study was to determine the mechanisms
by which estrogen affects mesenchymal stem cell function as a potential therapeutic measure during ex vivo ex-
pansion, before therapeutic use.
Methods:Asingle-steppurificationmethodusingadhesion to cell cultureplasticwas adopted to isolatemesenchymal
stem cells fromwild-type, estrogen receptor-a knockout, estrogen receptor-b knockout, and signal transducer and ac-
tivator of transcription 3 knockoutmice.Mesenchymal stem cells were treatedwith orwithout 17b-estradiol, estrogen
receptor-a agonist (propyl pyrazoletriol), and estrogen receptor-b agonist (diarylpropionitrile).
Results: 17b-estradiol significantly increased mesenchymal stem cell vascular endothelial growth factor
production in a dose-dependent manner. Both estrogen receptor-a and estrogen receptor-bwere expressed inmes-
enchymal stem cells. Administration of 17b-estradiol or estrogen receptor-a agonist (not estrogen receptor-b ag-
onist) elevated mesenchymal stem cell vascular endothelial growth factor, hypoxia inducible factor-1a
expression, and signal transducer and activator of transcription 3 activation. However, these effects were
neutralized in estrogen receptor-a knockout mesenchymal stem cells, not estrogen receptor-b knockout. Signal
transducer and activator of transcription 3 knockout abolished estrogen receptor-a–induced hypoxia inducible
factor-1a and subsequent vascular endothelial growth factor production.
Conclusion: 17b-estradiol–induced vascular endothelial growth factor production from mesenchymal stem cells
appears to be mediated through estrogen receptor-a–activated signal transducer and activator of transcription 3-
mediated hypoxia inducible factor-1a expression.E
T
/B
SSupplemental material is available online.
A rapidly growing body of evidence indicates that stem cells
may exert their beneficial effects on the injured heart in part
by paracrine actions.1-3 A number of in vitro and in vivo ex-
periments have suggested that vascular endothelial growth
factor (VEGF), a growth factor with potent angiogenic, che-
motactic and vasodilatory effects, is one important mediator
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doi:10.1016/j.jtcvs.2009.03.010The Journal of Thoracic and Cof these cardioprotective paracrine actions of stem cells.4-7
Additional studies have established that bone marrow cells
genetically modified to overexpress VEGF appear to be
even more effective for cardiac repair.6 Furthermore, our re-
cent study has shown that decreasing VEGF production by
mesenchymal stem cells (MSCs) with the use of small inter-
fering RNA abolishes their ability to protect myocardial
function after acute ischemia/reperfusion injury.2 Taken to-
gether, these data highlight the need for understanding
mechanisms of MSC VEGF production so that its produc-
tion may be increased and the therapeutic effectiveness of
stem cells may thereby be enhanced.
Sex differences exist in MSC paracrine growth factor pro-
duction. Female MSCs produce greater levels of VEGF
compared with male MSCs in response to toxic stimuli in vi-
tro and may also provide better cardioprotection.8 In addi-
tion, 17b-estradiol (E2) pretreatment of MSCs has been
reported to increase MSC VEGF production and may also
improve MSC-mediated cardiac protection.9 These results
indicate that estrogen may have a favorable effect on MSC
function. In addition, estrogen has been shown to regulate
cell function in a variety of stem/progenitor cells, includingardiovascular Surgery c Volume 138, Number 1 163
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E2 ¼ 17b-estradiol
ELISA ¼ enzyme-linked immunosorbent assay
ER ¼ estrogen receptor
DPN ¼ diarylpropiolnitrile
HIF ¼ hypoxia-inducible factor
KO ¼ knockout
MAPK ¼ mitogen-activated protein kinase
MSC ¼ mesenchymal stem cell
PPT ¼ propyl pyrazoletriol
STAT3 ¼ signal transducer and activator of
transcription-3
VEGF ¼ vascular endothelial growth factor
WT ¼ wild type
MSC-derived osteoblasts, human endothelial progenitor
cells, and embryonic cortical progenitor cells.10-13 Further-
more, estrogen treatment also up-regulates VEGF produc-
tion by differentiated cells.14,15 However, the mechanisms
by which E2 mediates VEGF production in MSCs remain
unknown.
Accumulating evidence demonstrates that hypoxia-induc-
ible factor (HIF)-1a plays a critical role in mediating VEGF
expression in a wide range of cell types in vitro.16-18 A num-
ber of growth factors, cytokines, and hormones have been
reported to activate HIF-1a–induced VEGF production.14,16
More important, HIF-1 mediates prostaglandin E2-induced
VEGF gene expression in cancer cells, suggesting that estro-
gen may mediate HIF-1–induced VEGF expression.17 It is
also known that estrogen initiates its biological activity by
binding to estrogen receptor (ER)-a or ERb. Activated ER
has been reported to induce HIF-1a activation and thereby
stimulates VEGF-mediated angiogenesis in osteoblasts.19
In addition, estrogen induces VEGF production in epithelial
cells through activation of HIF-1a and its recruitment to the
VEGF promotor by ERa.14 No information exists regarding
the effects of estrogen or its associated receptors on HIF-1a–
mediated VEGF production in MSCs. It is known, however,
that activation of HIF-1a by hypoxia may be linked to the
signal transducer and activator of transcription-3 (STAT3)
pathway.20,21 Estrogen-activated STAT3 has also been
noted to mediate physiologic and pathologic processes in
several cell types.22-24 Therefore, an investigation into
whether estrogen induces HIF-1a–mediated VEGF produc-
tion through activation of STAT3 in MSCs is worthwhile.
In the present study, we examined the effects and mecha-
nisms of action of E2 on VEGF production by MSCs. We
hypothesized that E2 would increase the stem cell release
of VEGF by ERa-induced STAT3 activation and subse-
quent HIF-1a expression.164 The Journal of Thoracic and Cardiovascular SurMATERIALS AND METHODS
Animals
C57BL/6J mice with and without targeted deletion or mutation of ERa
(ERa knockout [KO]; The Jackson Laboratory, Bar Harbor, ME) or ERb
(ERbKO; Taconic Farms, Inc, Hudson, NY) and the STAT3 deficiency
mouse line25 (a gift from Dr Fu’s group) were maintained in a quiet quaran-
tine room for 2 weeks before the experiments. The animal protocol was re-
viewed and approved by the Indiana Animal Care and Use Committee of
Indiana University. All animals received humane care in compliance with
the ‘‘Guide for the Care and Use of Laboratory Animals’’ (National Insti-
tutes of Health publication No. 85-23, revised 1985).
Preparation of Mouse Bone Marrow Mesenchymal
Stromal Cells
A single-step purification method using adhesion to cell culture plastic
was used as previously described.26 Briefly, mouse bonemarrowmesenchy-
mal stromal cells were harvested from male bilateral femurs and tibias by
removing the epiphyses and flushing the shaft with complete media (Is-
cove’s Modified Dulbecco’s Medium with 10% fetal bovine serum and
1% pen-strep; GIBCO Invitrogen, Carlsbad, CA). Cells were washed by
adding complete media, centrifuging for 5 minutes at 300 rpm at 24C
and removing supernatant. The cell pellet was then resuspended and cul-
tured with complete media at 37C, 5% CO2, and 90% humidity. MSCs
preferentially attached to the polystyrene surface; after 48 hours, nonadher-
ent cells in suspension were discarded. Fresh complete medium was added
and replaced every 3 days thereafter. MSCs were measured for CD markers
at passage 3 by flow cytometry, and they were double negative for the he-
matopoietic markers CD34 and CD45 (>90%), negative for the macro-
phage marker CD11b (>95%), and positive for the MSC marker CD44
(>95%).2 MSCs were used for experiments until passage 5.
Experimental Groups
After 5 passages,MSCswere plated in12well plates at a concentrationof 1
3 105 cells/well/mL. First, a dose response experiment was performed to de-
termine the concentrationofE2 thatwould causemaximumVEGFproduction
in wild-type (WT) stem cells. MSCs were treated with E2 (Sigma, St Louis,
MO) at 0, 1, 10, 100, 1000, and 10,000 nM, respectively, for 24 hours. Super-
natants were then collected for VEGF assay (enzyme-linked immunosorbent
assay [ELISA]). The experiment was repeated on 3 separate occasions.
WT, ERaKO, ERbKO, and STAT3KOMSCswere divided into 4 exper-
imental groups (triplicate wells per group: 1) control; 2) 100 nM of E2; 3)
100 nM of ERa agonist (propyl pyrazoletriol [PPT]; Tocris Cookson Inc,
Ellisville, MO); 4) 100 nM of ERb agonist (diarylpropiolnitrile [DPN]; Toc-
ris Cookson Inc). To distinguish acute or chronic effects of E2 on VEGF
production, supernatants were collected for VEGF assay (ELISA) after 6-
hour or 24-hour incubation. The experiment was repeated on 3 separate oc-
casions (n ¼ 6–11 wells/group). In addition, after different time incubation
(15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours), cell lysates were har-
vested for the assay of STAT3 activation by Western blot. Furthermore, ac-
tivation of mitogen-activated protein kinases (MAPKs: p38 MAPK, JNK,
and ERK1/2) and PI3K/Akt was also analyzed. Expression of nuclear
HIF-1a, ERa, and ERb was examined by using nuclear extracts.
Enzyme-Linked Immunosorbent Assay
VEGF in the MSC supernatant was determined by ELISA using a com-
mercially available ELISA set (R&D Systems Inc, Minneapolis, MN).
ELISA was performed according to the manufacturer’s instructions. All
samples and standards were measured in duplicate.
RNA Extraction, Reverse Transcription, and
Real-Time Polymerase Chain Reaction
Total RNAwas extracted from 4-hour incubatedWT, ERaKO, ERbKO,
and STAT3KOMSCswith or without E2, ERa agonist, and ERb agonist bygery c July 2009
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was subjected to cDNA synthesis using cloned avian myeloblastosis virus
first-strand cDNA synthesis kit (Invitrogen Life Technologies, Carlsbad,
CA). cDNA from each sample was analyzed for 18S rRNA (assay ID
Hs99999901_s1) and VEGFa (assay ID Mm00545913_s1) by using Taq-
Man gene expression assay (real-time polymerase chain reaction) (Applied
Biosystems, Foster City, CA). Each sample was assayed in duplicate.
Values were normalized to corresponding 18S rRNA real-time reverse tran-
scriptase-polymerase chain reaction values and expressed as the fold in-
crease relative to corresponding control.
Western Blotting
Western blot analysis was performed to measure MAPKs (p38 MAPK,
JNK, and ERK1/2), STAT3 activation, PI3K/Akt signaling, and HIF-1a.
Cells were lysed in cold RIPA buffer (Product No. R 0278: Sigma) and
centrifuged at 12,000 rpm for 10 minutes to get whole cell extracts. Nu-
clear extracts were isolated by using NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Pierce Biotechnology, Rockford, IL). The protein ex-
tracts (5 mg/lane) were subjected to electrophoresis on a 4% to 12% pre-
cise protein gel (Pierce Biotechnology) and transferred to a nitrocellulose
membrane. The membranes were incubated in 5% dry milk for 1 hour
and then incubated with the following primary antibodies: STAT3, phos-
phor-STAT3 (Tyr705), p38 MAPK, phosphor-p38 MAPK, JNK, phos-
phor-JNK (Thr183/Tyr185), ERK1/2, phosphor-ERK1/2 (Thr180/
Tyr182), PI3K, phosphor-PI3K, Akt, phosphor-Akt (1:1000 dilution,
Cell Signaling Technology, Beverly, MA), HIF-1a, ERa (MC-20), ERb
(H-150) (1:200 dilution, Santa Cruz Biotechnology, Inc, Santa Cruz,
CA), GAPDH (1:5000 dilution, Biodesign International, Saco, ME), or
TATA binding protein (1:2000 dilution, Abcam Inc, Cambridge, MA).
Membranes were then incubated with horseradish peroxidase-conjugated
goat anti-rabbit or anti-mouse immunoglobulin-G secondary antibody
(Pierce Biotechnology) and detection using SuperSignal West Pico Stable
Peroxide Solution (Pierce Biotechnology). Films were scanned using an
Epson Perfection 3200 Scanner (Epson America, Long Beach, CA), and
band density was analyzed using ImageJ software (National Institutes of
Health, Bethesda, MD).
Presentation of Data and Statistical Analysis
All reported values are mean  standard error of the mean. Data were
compared using 1-way analysis of variance with post hoc Tukey test or Stu-
dent t test.
RESULTS
E2 increases MSC production of VEGF in a dose-depen-
dent manner. Sex differences were noted inMSC production
of VEGF in response to injury, with higher levels of VEGF
observed in female MSCs.27 To determine what concentra-
tion of E2 would cause maximum VEGF production in
WT stem cells, different doses of E2 at 1, 10, 100, and
1000 nM, and 10 mM were adopted. Our data demonstratedThe Journal of Thoracic and Cthat E2 increased MSC VEGF production in a dose-depen-
dent manner in WT (Figure 1, A). Pharmacologic concentra-
tions of E2 at 100 nM yielded maximal VEGF release inWT
MSCs.
Estrogen Receptor-aMediates the 17b-Estradiol–
Induced Mesenchymal Stem Cell Release of Vascular
Endothelial Growth Factor
To examine which ER mediated the effects of E2 onMSC
VEGF production, the expression of ERa and ERb in MSCs
was first assessed. Our results indicated that both ERa and
ERb were present in nuclear extracts of MSCs as shown by
Western blot analysis (Figure 1,B). In addition, PPT, a selec-
tive ERa agonist, and DPN, a selective ERb agonist, were
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FIGURE 1. A, E2 increased MSC production of VEGF in a dose-depen-
dent manner (1, 10, 100, and 1000 nM, and 10 mM) (24-hour incubation).
B, Expression of ERa and ERb inMSCs. Nuclear extracts from 6 individual
samples were analyzed by Western blot. Results are mean  standard error
of the mean (SEM) (the experiment was repeated on 3 separate occasions).
*P<.01 versus control (0). #P<.01 versus 1 nM of E2. $P<.01 versus 10
nM of E2. VEGF, Vascular endothelial growth factor; ER, estrogen
receptor.TABLE 1. Protein and mRNA levels of vascular endothelial growth factor in mesenchymal stem cells from wild type, estrogen receptor-
a knockouts, or estrogen receptor-b knockouts treated with 17b-estradiol, the estrogen receptor-a agonist-propyl pyrazoletriol, or the estrogen
receptor-b agonist- diarylpropiolnitrile
VEGF protein (pg/mL) VEGF mRNA (folds of control)
C E2 PPT DPN C E2 PPT DPN
Wild type 701  32.6 909  55.4* 912  74.1* 736  51.2 1.15  0.07 1.66  0.22* 2.04  0.37* 1.25  0.40
ERaKO 552  34.5 543  59.3 550  59.8 540  49.1 1.65  0.65 1.77  0.15 1.56  0.57 1.43  0.26
ERbKO 603  23.9 693  33.7* 718  25.7* 586  29.8 1.08  0.08 1.36  0.04* 1.47  0.12 P ¼ .09 vs C 1.05  0.05
Mean  SEM. *P< .05 vs control.ardiovascular Surgery c Volume 138, Number 1 165
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agonist (PPT) significantly increased VEGF production in
WT MSCs by more than 200 pg/mL/105 cells (Table 1). In
addition, elevated VEGF mRNA levels, ranging from 1.5-
to 2-fold, were also noted in WT MSCs treated with E2 or
the ERa agonist (Table 1). However, the ERb agonist
(DPN) did not affect stem cell VEGF production (mRNA
and protein). To further confirm this observation, ERaKO
and ERbKO MSCs were adopted. In line with these results,
we found that ablation of ERa abolished E2- or ERa-induced
MSC VEGF expression (Table 1). However, application of
E2 or the ERa agonist maintained increased levels of
VEGF mRNA and protein expression in ERbKO MSCs
(Table 1).
17b-Estradiol–Increased Hypoxia-Inducible
Factor-1a Expression Is Mediated through
Estrogen Receptor-a
HIF-1a has been shown to mediate VEGF expression in
a variety of cell types by estrogen and other hormones. To
understand the molecular mechanisms of E2-increased
VEGF expression, we analyzed the expression of VEGF
regulator-HIF-1a by Western blot. As seen in Figure 2,
HIF-1a expression was increased by more than 2 times
in WT MSCs 30 minutes and 1 hour after administration
of E2. In addition, the ERa agonist also elevated HIF-1a
expression by 3 times at 30 minutes and 1 hour. However,
the selective ERb agonist did not affect HIF-1a expression.
These data suggested that E2 induced HIF-1a expression
via the ERa.
Estrogen Receptor-aMediates 17b-Estradiol–
Induced Signal Transducer and Activator of
Transcription-3 Activation
As seen in Figure 3, A, Western blot analysis showed
that there was a 2-fold increase in STAT3 activation
(exhibited as phosphorylated STAT3) 15 minutes after E2
or ERa agonist treatment. This elevated activation of
STAT3 was also noted within 30 minutes of treatments,
whereas total STAT3 levels were not changed. However,
DPN, the selective ERb agonist, did not increase STAT3
activation in MSCs. In addition, the trend of increased
p-STAT3 was noted to be maintained until 2 hours after ad-
ministration of E2 or ERa agonist in WT MSCs. After 4
hours of treatment, the ERa agonist-induced STAT3 acti-
vation normalized.
Basal levels of p-STAT3 were significantly higher in WT
MSCs than in ERaKO (7-fold) or ERbKO MSCs (2-fold)
(Figure 3, B). However, ablation of ERa or ERb did not
change total STAT3 expression. Notably, deficiency of
ERa neutralized E2- or ERa-induced STAT3 activation in
MSCs (Figure 3, C).166 The Journal of Thoracic and Cardiovascular SurFIGURE 2. Nuclear levels of HIF-1a are increased by addition of E2 or the
ERa agonist-PPT (ERa), but not the ERb agonist-DPN (ERb) in WT
MSCs. A, Nuclear HIF-1a expression 30 minutes after E2, ERa agonist,
and ERb agonist treatment. B, Nuclear levels of HIF-1a at 1 hour after
addition of E2, ERa agonist, and ERb agonist. Shown are representative im-
munoblots. Bar graph indicates relative density (%) of HIF-1a compared
with nuclear loading control TATA binding protein. Mean  SEM. *P<
.05 versus control. TBP, TATA binding protein; ER, estrogen receptor;
HIF, hypoxia-inducible factor.gery c July 2009
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Wang et al Evolving Technology/Basic ScienceFIGURE 3. A, Effects of E2, ERa agonist, or ERb agonist on STAT3 activation. Increased STAT3 activation is noted within 15 and 30 minutes after E2 or
ERa agonist treatment, and this high level of p-STAT3 is maintained until 2 hours. Shown are representative immunoblots. B, Basal levels of STAT3 acti-
vation inMSCs fromWT, ERaKO, and ERbKOmice (2 lanes/group). C, E2 or the ERa agonist does not induce STAT3 activation in ERaKOMSCs (2 lanes/
group). Bar graph indicates relative density of p-STAT3 compared with total STAT3 (%). Mean SEM. *P<.05. **P<.01. ***P<.001 versus control or
WT. #P< .01 versus ERbKO. STAT3, Signal transducer and activator of transcription-3; ER, estrogen receptor; WT, wild type; KO, knockout.Estrogen Receptor-a–Activated Signal Transducer
and Activator of Transcription-3 Induces
Hypoxia-Inducible Factor-1a Expression and
Vascular Endothelial Growth Factor Production
STAT3 activation has been linked to up-regulation of
HIF-1a expression and VEGF production. We already
found that E2 induced STAT3 activation and that HIF-1a
expression was mediated through ERa. However, it wasThe Journal of Thoracic and Cunclear whether ERa-induced STAT3 activation would stim-
ulate HIF-1a expression in MSCs. Therefore, STAT3KO
MSCs were used to examine this mechanism. As shown in
Figure 4, deficiency of STAT3 abolished E2- or ERa
agonist-induced HIF-1a expression.
STAT3KO MSCs were also adopted to further determine
the effects of STAT3 on ERa-mediated VEGF production.
Significantly increased VEGF production was observed inardiovascular Surgery c Volume 138, Number 1 167
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treatment with E2 or the ERa agonist (Figure 5, A, C). How-
ever, these elevated VEGF protein levels were neutralized in
STAT3KOMSCs (Figure 5, B, D). In addition, deficiency of
STAT3 also abolished E2- or ERa-increased VEGF mRNA
levels (Figure 5, E, F).
FIGURE 4. Increased nuclear levels of HIF-1a by E2 or ERa agonist are
absent in STAT3KO MSCs. A, Nuclear HIF-1a expression at 30 minutes
after E2, ERa, and ERb treatment in STAT3KO MSCs. B, Nuclear levels
of HIF-1a 1 hour after administration of E2, ERa, and ERb agonists in
STAT3KO MSCs. Shown are representative immunoblots. Bar graph indi-
cates relative density (%) of HIF-1a compared with nuclear loading control
TATA binding protein. Mean SEM. TBP, TATA binding protein; ER, es-
trogen receptor; HIF, hypoxia-inducible factor.168 The Journal of Thoracic and Cardiovascular SuEffects of Estrogen Receptors on the Activation of
Mitogen-Activated Protein Kinases and PI3K/Akt
Signaling in 17b-Estradiol–Treated Mesenchymal
Stem Cells
Given that estrogen stimulates the MAPK pathway and
activates PI3K/Akt signaling, and that both the MAPK path-
way and PI3K/Akt have been linked to HIF-1a expres-
sion,14,17,28 we determined the effects of E2, the ERa
agonist, and the ERb agonist on activation of MAPKs and
PI3K/Akt in MSCs. The results from Western blot indicated
that administration of E2, PPT, or DPN did not change acti-
vation of p38 MAPK or ERK1/2 in MSCs within 30 min-
utes, 1 hour, or 2 hours after administration (Figure E1, A,
C). However, a transient decrease in JNK activation was ob-
served 30 minutes after treatment with E2, ERa agonist, or
ERb agonist (Figure E1, B). This decreased pattern in JNK
activation was also noted in STAT3KO MSCs (data not
shown). This suggests that changes in JNK activation are
not involved in STAT3 pathway. In addition, E2, the ERa
agonist, and the ERb agonist did not affect activation of
PI3K and Akt (Figure E2).
DISCUSSION
VEGF is a critical factor in angiogenesis and has been
shown to facilitate stem cell paracrine protection in the is-
chemic myocardium.3,6,7 Accumulating evidence has dem-
onstrated that estrogen plays a role in modulating stem cell
function and mediating VEGF production.9-13 Our previous
study further suggested that sex differences exist in MSC
VEGF production, with relatively higher levels of VEGF be-
ing produced by female MSCs.27 These sex disparities in
stem cell VEGF production correlate to biologically relevant
sex differences in stem cell-mediated cardioprotection, be-
cause MSCs from females confer greater cardioprotection
compared with male MSCs.8 In addition, E2-pretreated
MSCs have exhibited increased VEGF production and better
cardiac protection.9 These studies have led to the important
appreciation that estrogen may facilitate the induction of
stem cell VEGF production, which may enhance the thera-
peutic effectiveness of MSCs.
Estrogen initiates its biological effects by interacting with
multiple ERs. Two ER subtypes have been identified: ERa
and ERb, both of which belong to the nuclear receptor
gene family of transcription factors. In this study, we provide
the evidence that E2 can increase MSC production of VEGF
in a dose-dependent manner. Our results also indicate that
both ERa and ERb are expressed in MSCs and that E2-in-
duced VEGF expression (both mRNA and protein levels)
is mediated through ERa, but not ERb.
However, the downstream signaling cascades associated
with ERa-induced VEGF production in MSCs have not
been fully elucidated. HIF-1 is the primary mediator of the
physiologic responses associated with reduction in tissue ox-
ygen tension (hypoxia) and plays an important role in VEGFrgery c July 2009
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FIGURE 5. Protein and mRNA levels of VEGF in MSCs from WT and STAT3KO mice after administration of E2, ERa agonist-PPT (ERa), and ERb
agonist-DPN (ERb). E2 or ERa agonist increases VEGF secretion at 6-hour (A) and 24-hour (C) treatments, as well as VEGF mRNA (E) in WT MSCs.
However, STAT3KO abolishes E2- or ERa-induced VEGF production at 6-hour (B) and 24-hour (D) treatments, as well as VEGF gene expression (F).
Mean SEM. *P<.05 versus control. STAT3, Signal transducer and activator of transcription-3; ER, estrogen receptor; VEGF, vascular endothelial growth
factor; KO, knockout.transcriptional activation.29,30 Transcription factor HIF-1
consists of 2 subunits: HIF-1a, the hypoxia-induced compo-
nent, and HIF-1b, which is expressed constitutively. HIF-1a
is rapidly degraded in normoxic cells. However, under con-
ditions of low oxygen tension, HIF-1a stabilizes as the result
of hypoxia-prevented degradation. HIF-1a has been re-
ported to regulate the induction of VEGF expression in sev-
eral cell types under normoxic conditions.9,14,15 In vascular
smooth muscle cells without hypoxia, angiotensin II up-reg-
ulates HIF-1a–induced VEGF expression.18 Treatment with
insulin-like growth factor 1 has also been shown to elevate
HIF-1a–induced VEGF mRNA and protein levels in cancer
cells.14 Therefore, the activation of HIF-1amay be required
for estrogen-induced VEGF expression via 1 or moreThe Journal of Thoracic and CERs.17,19 Indeed, ERa-activated HIF-1a has been shown
to mediate estrogen-induced VEGF production in epithelial
cells.14 In the current study, our data regarding E2- or ERa-
increased HIF-1a expression inMSCs are in line with results
from previous studies and further confirm that non-hypoxic
stimuli can induce HIF-1a. In addition, we observed that E2-
elevated HIF-1a is likely mediated by ERa and not ERb.
These results suggest that E2-increased VEGF mRNA and
protein levels are likely mediated through ERa-induced
HIF-1a in MSCs.
STAT3 has been implicated in a variety of cellular func-
tions, including cell survival/apoptosis, proliferation, inflam-
mation, and angiogenesis.26,31,32 Activation of STAT3 has
been found in a wide range of tissues and organs, and appearsardiovascular Surgery c Volume 138, Number 1 169
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terest, STAT3 has been reported to be a direct target gene for
estradiol. Not only has chronic estradiol treatment been
shown to induce STAT3 activation, but acute treatment
with the ERa agonist PPT has also been shown to up-regulate
STAT3 expression in the mouse liver.22,33 In addition, E2-
acitvated STAT3 plays a role in conveying non-genomic ef-
fects of estrogen in endothelial cells.24 Moreover, active
STAT3 signaling by raloxifene plus E2 has been shown to
modulate proliferation of vascular smooth muscle cells and
human thoracic endothelial cells.23 Our results indicate that
administration of E2 or the ERa agonist PPT increases activa-
tion of STAT3 in MSCs. In addition, significantly decreased
basal levels of active STAT3 have been observed in ER KO
MSCs with the lowest levels being noted in ERaKOs. Fur-
thermore, deficiency ofERa abolishedE2- orERa agonist-in-
creased STAT3 activation. Taken together, these data suggest
that cross-talk exists between STAT3 and estrogen signaling,
and that ERa is required forE2-mediatedSTAT3activation in
MSCs. However, we recognized that STAT3KO was used in
this study and ablation of a complete signaling moiety might
cause some nonspecific effects. Therefore, further investiga-
tion by using small interferingRNAof STAT3 or transfection
of dominant negative STAT3 is required to determine the de-
tailedmechanisms bywhich STAT3mediatesMSC function.
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FIGURE 6. Model for the mechanism of VEGF production mediated by
ERa. STAT3, Signal transducer and activator of transcription-3; ER, estro-
gen receptor; VEGF, vascular endothelial growth factor; MAPK, mitogen-
activated protein kinase.170 The Journal of Thoracic and Cardiovascular SurRecent evidence has demonstrated that STAT3 is a direct
transcriptional activator of VEGF expression in a variety of
cell types.21,26,31,32 Our previous study has indicated that
STAT3 is required for both basal and stress-induced VEGF
production in MSCs.26 Overexpression of active STAT3 in
cardiomyocytes increased myocardial VEGF production,34
and active STAT3-mediated HIF-1a has been reported to
up-regulate transcription of the VEGF promoter in human
renal carcinoma cells.20 Blockade of STAT3 down-regulates
HIF-1a and thereby decreases VEGF expression.35 More-
over, active STAT3 has been shown to stabilize and increase
HIF-1a protein levels by inhibition of HIF-1a degradation
and acceleration of its synthesis.20 Therefore, it can be pro-
posed that STAT3 signaling may mediate MSC production
of VEGF through regulation of HIF-1a. In the current study,
we found that ablation of STAT3 neutralized E2- or ERa-in-
ducedHIF-1a expression, and thus abolished E2- or ERa-in-
creased VEGF mRNA and protein expression in MSCs.
Although Gray and colleagues36 have reported that maxi-
mum transcription of VEGF expression requires the binding
of both STAT3 and HIF-1a to the VEGF promoter in carci-
nomas, the detailed mechanistic interactions of STAT3 and
HIF-1a in the regulation of VEGF promoter requires further
investigation.
CONCLUSIONS
On the basis of these findings, ERa-activated STAT3 in-
creases stem cell HIF-1a–mediated VEGF expression in-
duced by the addition of estrogen (Figure 6). A better
understanding of the effects of gender, estrogen, and ER
may allow for the modification of stem cells in vitro to max-
imize stem cell paracrine protective properties, such as the
expression of VEGF.
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Evolving Technology/Basic Science Wang et alFIGURE E1. Activation of p38 MAPK, JNK, and ERK1/2 in WT MSCs
30 minutes, 1 hour, and 2 hours after administration of E2, ERa agonist, and
ERb agonist. A, p-p38 MAPK and total-p38 MAPK. B, Phosphor- and to-
tal-JNK. C, p-ERK1/2 and total-ERK1/2. Two lanes/group are shown. ER,
Estrogen receptor.
FIGURE E2. Activation of PI3K and Akt in WT MSCs 30 minutes, 1
hour, and 2 hours after treatment with E2, ERa agonist, and ERb agonist.
A, p-PI3K and total-PI3K. B, Phosphor and total Akt. Shown are 2 lanes/
group. ER, Estrogen receptor.171.e1 The Journal of Thoracic and Cardiovascular Surgery c July 2009
